Product Approval / Regulatory Milestone
Alembic Pharma Receives USFDA Approval for Methotrexate Injection
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals has received USFDA final approval for its Methotrexate Injection USP in both multi-dose and single-dose formats, strengthening its generics portfolio in the US market.
PRICE-SENSITIVE TRIGGER
Event: USFDA final approval for ANDA product
Type: Product Approval / Regulatory Milestone
Impact: Positive
Immediate Effect: Enhances product pipeline and opens revenue opportunities in the US generics market
Financial Snapshot
- Financial Data Available: Not disclosed
Highlights
Total ANDA approvals now stand at 236 (218 final + 18 tentative)
What Happened ?
Alembic Pharmaceuticals announced that it has received USFDA final approval for:
- Methotrexate Injection USP
- 50 mg/2 mL (Multi-dose)
- 1 g/40 mL (Single-dose)
This approval is for its Abbreviated New Drug Application (ANDA).
key highlights
- Therapeutically equivalent to reference drug (Hospira Inc.)
- Used in treatment of:
- Cancer (leukemia, lymphoma, breast cancer, etc.)
- Autoimmune diseases (RA, psoriasis, etc.)
- Expands Alembic’s injectable portfolio in US market
- Strengthens presence in complex generics segment
Insight:
Injectables are a higher-margin, entry-barrier segment compared to oral generics.
Risk Analysis
Key Risks
- Pricing pressure in US generics market
- Competition from other generic players
- Regulatory compliance and manufacturing risks
- Margin volatility due to US market dynamics
Worst Case Scenario
If pricing pressure is high or competition intensifies, revenue contribution from this product may be limited
Risk Level: Medium
Company Commentary
- Approval strengthens Alembic’s US generics portfolio
- Continues expansion in injectables and complex products
(No direct quotes disclosed)
Official Exchange Filing: Alembic Pharmaceuticals Limited